Lost password ?
<< Back to Equity Research
Gulf Pharmaceutical
JULPHAR, THE MEDICINES WITHDRAWAL QUIVER
Feb 28 - Overall, it was not a great idea to be exposed to the Pharma sector in the last months. AlphaMena’s pharma coverage has lost more than 11% YTD. In our last piece on Julphar (Buy, UAE), our ...
Executive summary
Conflict of Interest
Pages 40
Language English
Publish on February 28, 2019
€ 500
VAT Exl.
You might be also interested by these reports :
Apr 25 AM
UNIMED
Double-digit growth in Q1
Apr 15 PM
Idea Kicker
JULPHAR, WAITING FOR A SAFETY MARGIN
Mar 19 AM
Gulf Pharmaceutical
A better Q4 lifted our Target Price
Mar 16 PM
Gulf Pharmaceutical
A hit from outside GCC revenues in 2023
FIND A REPORT
CONCEPT
Each company is researched in depth using a structured robust and transparent process.

AlphaMena provides analyses based upon exhaustive and homogeneous information which allows to compare stocks geographically, sector-wise, and by thematic.

The analyses include actuarial as well as off balance-sheet data.
BloombergStarmineFactsetReutersCapital IQ